POF Asia Direct

Introducing POF Asia Direct

 

Since our inception, Phillips Ormonde Fitzpatrick (POF) has worked with clients around the world. While in the last century (and the one before!), we focused on our clients’ interests in Europe and America, the 21st century has seen greater focus on the Asian region as a driver of growth. In response to this growth, and Australia’s key position in the region, POF has been working with our clients to develop a ‘one stop shop’ for IP protection throughout South East Asia.

How does it work?

Over the past decade, we have been working with clients to bundle their IP interests in the South East Asian region, allowing for cost effective management of IP through a single point of contact. POF represents clients directly before IP offices in Australia, New Zealand, Papua New Guinea and Vanuatu. In other South East Asian Countries, we have established trusted relationships with IP associates from whom we receive preferential treatment and fees.

 

What we do

POF’s full suite of services is available in South East Asia. Patent, trade mark and design services include:

  • Filing
  • IP portfolio management
  • Examination
  • Translations
  • Prosecution
  • Grant or registration of applications.

Where we work

Countries where POF South East Asia Direct operates include Australia, New Zealand, Papua New Guinea, Indonesia, Malaysia, India, Taiwan, Thailand, Bangladesh, Sri Lanka, Philippines, Singapore and Vietnam. A full list of countries is available on request.

Advantages of POF Asia Direct

  • One point of contact for queries, requests, instructions and invoices
  • Cost-effective bundled IP management across the region
  • Protection for your intellectual property wherever you need it across the region
  • Your choice of currency for invoicing.

 

For more information about how we can protect your portfolio in South East Asia, please contact us at attorney@pof.com.au

 

 

 

BSc FIPTA MRACI Cchem

David joined the firm in 1983, but took a hiatus to work in the Intellectual Property Department of ICI Pharmaceuticals (now AstraZeneca) in England during 1986-1987.